retatrutide clinical trials weight loss The drug is manufactured by Eli Lilly and is not FDA approved, however, one person gained access to the prescription through a program that approves experimental treatments for patients traditionally suffering Retatrutide (“reta”) is an experimental

The increase in GLP-1RA use going forward is expected to have fundamental impacts on broader consumer and commercial behavior

The landscape of medical weight loss has fundamentally changed

6-10 GLP-1 receptor agonists work to lower glycemia via several mechanisms

Bank of America Securities also trimmed its target to $21 from $26 and reiterated an Underperform rating

Obesity 33(3):452462 [DOI] [PMC free article] [PubMed] [Google Scholar] 81.Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S et al (2023) Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes

Generally, semaglutide GLP-1 is considered a relatively expensive medication, with monthly costs ranging from several hundred to over a thousand dollars